$7.24
0.42% day before yesterday
Nasdaq, May 30, 10:07 pm CET
ISIN
US30233G1004
Symbol
EYPT
Sector
Industry

EyePoint Pharmaceuticals, Inc. Stock price

$7.24
+0.42 6.16% 1M
-1.52 17.35% 6M
-0.21 2.82% YTD
-3.51 32.65% 1Y
-2.45 25.28% 3Y
-1.16 13.81% 5Y
-31.36 81.24% 10Y
Nasdaq, Closing price Fri, May 30 2025
+0.03 0.42%
ISIN
US30233G1004
Symbol
EYPT
Sector
Industry

Key metrics

Market capitalization $498.20m
Enterprise Value $180.01m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.21
P/S ratio (TTM) P/S ratio 8.89
P/B ratio (TTM) P/B ratio 1.67
Revenue growth (TTM) Revenue growth 12.04%
Revenue (TTM) Revenue $56.04m
EBIT (operating result TTM) EBIT $-161.37m
Free Cash Flow (TTM) Free Cash Flow $-151.31m
Cash position $318.19m
EPS (TTM) EPS $-2.10
P/E forward negative
P/S forward 12.46
EV/Sales forward 4.50
Short interest 12.56%
Show more

Is EyePoint Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.

EyePoint Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a EyePoint Pharmaceuticals, Inc. forecast:

13x Buy
100%

Analyst Opinions

13 Analysts have issued a EyePoint Pharmaceuticals, Inc. forecast:

Buy
100%

Financial data from EyePoint Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
56 56
12% 12%
100%
- Direct Costs 3.76 3.76
21% 21%
7%
52 52
15% 15%
93%
- Selling and Administrative Expenses 56 56
8% 8%
100%
- Research and Development Expense 158 158
96% 96%
282%
-160 -160
82% 82%
-285%
- Depreciation and Amortization 1.73 1.73
162% 162%
3%
EBIT (Operating Income) EBIT -161 -161
83% 83%
-288%
Net Profit -147 -147
86% 86%
-262%

In millions USD.

Don't miss a Thing! We will send you all news about EyePoint Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

EyePoint Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
4 days ago
WATERTOWN, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate in fireside chats at the following upcoming investor conferences:
Neutral
GlobeNewsWire
5 days ago
– Over 400 patients enrolled and randomized over a seven-month period, driven by strong physician and patient interest –
Neutral
GlobeNewsWire
16 days ago
WATERTOWN, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in a...
More EyePoint Pharmaceuticals, Inc. News

Company Profile

EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development and commercializing of ophthalmic products. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

Head office United States
CEO Jay Duker
Employees 165
Founded 1987
Website eyepointpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today